Payment overview · 2025
General Payments
$37,817.65
81 reported records · 22 companies
Healthcare provider profile · identity verified
Kamran Ayub, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · OAK LAWN, IL · NPI 1942317243
Verified facts
What the public records show
CMS Open Payments records show Kamran Ayub, MD received $37,817.65 in general payments during 2025 across 81 reported records.
Aimmune Therapeutics, Inc. accounted for 46.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17,487.45 | 46.2% | 15 | 2025 |
| Pinnacle Biologics, Inc | Unresolved — no canonical attribution shown | $6,536.27 | 17.3% | 6 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $6,464.14 | 17.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,617.33 | 9.6% | 15 | 2025 |
| Olympus Corporation of the Americas | Unresolved — no canonical attribution shown | $892.65 | 2.4% | 7 | 2025 |
| Olympus Medical Systems Corporation | Unresolved — no canonical attribution shown | $875.00 | 2.3% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $418.01 | 1.1% | 5 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $268.36 | 0.7% | 2 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $239.68 | 0.6% | 2 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $178.99 | 0.5% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $143.60 | 0.4% | 1 | 2025 |
| Micro-tech Endoscopy USA, Inc. | Unresolved — no canonical attribution shown | $122.47 | 0.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.62 | 0.3% | 1 | 2025 |
| AnX Robotica Corp | Unresolved — no canonical attribution shown | $100.00 | 0.3% | 1 | 2025 |
| Mauna Kea Technologies, Inc. | Unresolved — no canonical attribution shown | $77.77 | 0.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$75.56 | 0.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $55.82 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.10 | 0.1% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $38.58 | 0.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $25.42 | 0.1% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $18.65 | 0.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.18 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,675.00 | 5 |
| Honoraria | $9,750.00 | 1 |
| Consulting Fee | $6,275.00 | 2 |
| Travel and Lodging | $4,976.74 | 14 |
| Food and Beverage | $2,700.91 | 58 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,440.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17,487.45 | 15 | 2025 |
Source payment records
|
|||||
| Photofrin Normalized: photofrin |
Drug | Pinnacle Biologics, Inc | $6,536.27 | 6 | 2025 |
Source payment records
|
|||||
| ESOPHYX Normalized: esophyx |
Device | Merit Medical Systems Inc | $6,464.14 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3,450.00 | 2 | 2025 |
Source payment records
|
|||||
| DISPOSABLE DISTAL ATTACHMENT Normalized: disposable distal attachment |
Device | Olympus Corporation of the Americas | $892.65 | 7 | 2025 |
Source payment records
|
|||||
| Olympus Normalized: olympus |
Device | Olympus Corporation of the Americas | $892.65 | 7 | 2025 |
Source payment records
|
|||||
| Single Use Electrosurgical Knife KD-655 Normalized: single use electrosurgical knife kd 655 |
Device | Olympus Corporation of the Americas | $892.65 | 7 | 2025 |
Source payment records
|
|||||
| EVIS EXERA III DUODENOVIDEOSCOPE Normalized: evis exera iii duodenovideoscope |
Device | Olympus Medical Systems Corporation | $875.00 | 1 | 2025 |
Source payment records
|
|||||
| CONMED BILIARY Normalized: conmed biliary |
Device | CONMED Corporation | $249.82 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $239.68 | 2 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $178.99 | 7 | 2025 |
Source payment records
|
|||||
| CONMED GENERATORS Normalized: conmed generators |
Device | CONMED Corporation | $168.19 | 1 | 2025 |
Source payment records
|
|||||
| FUSION Normalized: fusion |
Device | Cook Medical LLC | $148.36 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $143.60 | 1 | 2025 |
Source payment records
|
|||||
| eyeMAX Normalized: eyemax |
Device | Micro-tech Endoscopy USA, Inc. | $122.47 | 1 | 2025 |
Source payment records
|
|||||
| FUSION QUATTRO Normalized: fusion quattro |
Device | Cook Medical LLC | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $115.62 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $107.10 | 10 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $92.33 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $60.23 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $60.23 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $55.82 | 2 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $52.10 | 2 | 2025 |
Source payment records
|
|||||
| ENDOFLIP Normalized: endoflip |
Device | Medtronic, Inc. | $47.41 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $27.37 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| CONMED HEMOSTASIS Normalized: conmed hemostasis |
Device | CONMED Corporation | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 48 |
| Metoclopramide Hcl | Metoclopramide Hcl | 74 | 68 |
| Omeprazole | Omeprazole | 55 | 24 |
| Famotidine | Famotidine | 20 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37,817.65 · 81 records | Aimmune Therapeutics, Inc. | CONMED BILIARY, CONMED GENERATORS, CONMED HEMOSTASIS, CREON, DISPOSABLE DISTAL ATTACHMENT, DUPIXENT, Da Vinci Surgical System, ENDOFLIP, ESOPHYX, EVIS EXERA III DUODENOVIDEOSCOPE, FUSION, FUSION QUATTRO, General - Therapies, IBSRELA, INTERSTIM, LINZESS, Olympus, PANCREAZE, Photofrin, REZDIFFRA, RINVOQ, SIMPONI, SIMPONI ARIA, SKYRIZI, STELARA, Single Use Electrosurgical Knife KD-655, Sucraid, TREMFYA, VELSIPITY, VIBERZI, VOQUEZNA, XELJANZ, ZENPEP, eyeMAX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error